ATE535241T1 - Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie - Google Patents
Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämieInfo
- Publication number
- ATE535241T1 ATE535241T1 AT08857282T AT08857282T ATE535241T1 AT E535241 T1 ATE535241 T1 AT E535241T1 AT 08857282 T AT08857282 T AT 08857282T AT 08857282 T AT08857282 T AT 08857282T AT E535241 T1 ATE535241 T1 AT E535241T1
- Authority
- AT
- Austria
- Prior art keywords
- azaindolyl
- indolyl
- leukemia
- treatment
- phenyl
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07023588 | 2007-12-05 | ||
| PCT/EP2008/066776 WO2009071620A1 (en) | 2007-12-05 | 2008-12-04 | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535241T1 true ATE535241T1 (de) | 2011-12-15 |
Family
ID=40328303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08857282T ATE535241T1 (de) | 2007-12-05 | 2008-12-04 | Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8841319B2 (de) |
| EP (1) | EP2217231B1 (de) |
| JP (1) | JP5576290B2 (de) |
| AT (1) | ATE535241T1 (de) |
| AU (1) | AU2008333215B2 (de) |
| CA (1) | CA2707554C (de) |
| WO (1) | WO2009071620A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120772A1 (es) | 2009-04-14 | 2012-06-27 | Lilly Co Eli | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia |
| EP2343291A1 (de) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren |
| EP2338486A1 (de) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Derivaten zurVerwendung in der Behandlung von Colon und Magen Adenocarzinoma |
| EP2474541A1 (de) * | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren |
| KR20150027267A (ko) | 2012-06-29 | 2015-03-11 | 화이자 인코포레이티드 | LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘 |
| EP2928465B1 (de) * | 2012-12-10 | 2020-11-18 | Centogene GmbH | Verwendung von maleimidderivaten zur vorbeugung und behandlung von krebs |
| WO2014090398A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
| JP6873980B2 (ja) | 2015-09-14 | 2021-05-19 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体 |
| EP3187495A1 (de) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0115193B1 (pt) * | 2000-11-07 | 2016-08-09 | Novartis Ag | derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende |
| JP2005529918A (ja) * | 2002-05-08 | 2005-10-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換されたピロリンキナーゼ阻害剤 |
| AU2003240517A1 (en) | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| CA2520590A1 (en) | 2003-03-27 | 2004-11-04 | Janssen Pharmaceutica, N.V. | Substituted pyrroline kinase inhibitors |
| CA2589127C (en) | 2004-12-08 | 2013-02-05 | Johannes Gutenberg-Universitat Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
-
2008
- 2008-12-04 AT AT08857282T patent/ATE535241T1/de active
- 2008-12-04 WO PCT/EP2008/066776 patent/WO2009071620A1/en not_active Ceased
- 2008-12-04 EP EP08857282A patent/EP2217231B1/de not_active Not-in-force
- 2008-12-04 CA CA2707554A patent/CA2707554C/en not_active Expired - Fee Related
- 2008-12-04 AU AU2008333215A patent/AU2008333215B2/en not_active Ceased
- 2008-12-04 US US12/746,630 patent/US8841319B2/en not_active Expired - Fee Related
- 2008-12-04 JP JP2010536454A patent/JP5576290B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110028415A1 (en) | 2011-02-03 |
| US8841319B2 (en) | 2014-09-23 |
| CA2707554A1 (en) | 2009-06-11 |
| EP2217231A1 (de) | 2010-08-18 |
| CA2707554C (en) | 2015-06-30 |
| WO2009071620A1 (en) | 2009-06-11 |
| AU2008333215B2 (en) | 2013-06-13 |
| JP2011506288A (ja) | 2011-03-03 |
| JP5576290B2 (ja) | 2014-08-20 |
| AU2008333215A1 (en) | 2009-06-11 |
| EP2217231B1 (de) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535241T1 (de) | Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| HUP0303637A2 (hu) | Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények | |
| NO20061406L (no) | Organiske forbindelser | |
| EA200501617A1 (ru) | Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы | |
| CY1113099T1 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
| EA200702497A1 (ru) | Замещенные арилпиразолы для применения против паразитов | |
| CY1109821T1 (el) | Ενωσεις πιπεραζινης με ζιζανιοκτονα δραση | |
| TW200833675A (en) | Nicotinamide derivatives | |
| EA201200875A1 (ru) | Ингибиторы сфингозинкиназы | |
| NO20083598L (no) | Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| CY1106881T1 (el) | (3-οξο-3,4-διυδρο-κινοξαλιν-2-υλο-αμινο) - βενζαμιδικα παραγωγα και σχετικες ενωσεις ως αναστολεις της φωσφορυλασης γλυκογονου για την αντιμετωπιση του διαβητη και της παχυσαρκιας. | |
| NO20083207L (no) | Inhibitorer av IAP | |
| NO20075384L (no) | Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer. | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| EA201200863A1 (ru) | Ингибиторы сфингозинкиназы | |
| AR070797A1 (es) | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| CY1114865T1 (el) | Νεοι αναστολεις seh και η χρηση toyς | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| TW200612936A (en) | Indole derivatives | |
| AR070635A1 (es) | DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS. |